Biodesix (BDSX) Net Equity Issued and Repurchased (2022 - 2026)

Biodesix (BDSX) has 5 years of Net Equity Issued and Repurchased data on file, last reported at $17.2 million in Q1 2026.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $17.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.5 million (changed N/A YoY) and the FY2025 annual result came in at $7.3 million, down 86.84% from the prior year.
• Net Equity Issued and Repurchased grew to $17.2 million in Q1 2026, from $2.3 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $55.0 million in Q2 2024 to a low of $625000.0 in Q1 2024.
• A 5-year average of $14.1 million and a median of $5.0 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 750.0% in 2023, down 70.65% in 2023.
• Tracing BDSX's Net Equity Issued and Repurchased over 5 years: stood at $41.6 million in 2022, then slumped by 70.65% to $12.2 million in 2023, then jumped by 350.82% to $55.0 million in 2024, then tumbled by 95.78% to $2.3 million in 2025, then soared by 641.98% to $17.2 million in 2026.
• The last three Net Equity Issued and Repurchased figures came in at $17.2 million (Q1 2026), $2.3 million (Q4 2025), and $5.0 million (Q3 2025), per Business Quant data.